In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Homology Medicines nets $135.1mm via FOPO

Executive Summary

Genetic medicines developer Homology Medicines Inc. netted $135.1mm in its follow-on public offering of 6.39mm common shares (including full exercise of the overallotment) at $22.50. The company will use the proceeds to move its lead gene therapy program HMI102 for adults with phenylketonuria through a Phase I/II trial; to advance both HMI202 for metachromatic leukodystrophy and HMI103 for pediatric PKU through IND-enabling studies and possibly into the clinic; to move other pipeline programs through preclinical development; to further expand its intellectual property portfolio; and to potentially expand its manufacturing capacity.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies